Evidence for increased circulating procoagulant phospholipids in patients with COVID-19 pneumonia and their prognostic role
- 2 September 2020
- journal article
- letter
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 59 (2) , e53-e55
Abstract
Article Evidence for increased circulating procoagulant phospholipids in patients with COVID-19 pneumonia and their prognostic role was published on February 1, 2021 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 59, issue 2).Keywords
This publication has 6 references indexed in Scilit:
- Coagulation abnormalities and thrombosis in patients with COVID-19The Lancet Haematology, 2020
- COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-UpJACC, 2020
- Hematological findings and complications of COVID‐19American Journal of Hematology, 2020
- Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumoniaJournal of Thrombosis and Haemostasis, 2020
- Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of AmericaAmerican Journal of Respiratory and Critical Care Medicine, 2019
- Role of microparticles in sepsisBritish Journal of Anaesthesia, 2012